Earnings Feed

COO

Healthcare

The company successfully resolved previous manufacturing constraints that limited the full competition of MyDay, marking a key turning point.
Full sales execution capabilities for MyDay are now in place, enabling accelerated global rollout of fitting sets and trial lenses.
Management highlighted that resolving manufacturing issues was crucial for meeting increasing demand and driving sustained growth.
Renewed large contracts and new private label agreements for MyDay are expected to significantly contribute to future growth.
The company’s confidence in MyDay’s upside is supported by these recent wins and the product’s expanding availability.
Management emphasized that capacity expansion and operational improvements are central to regaining market momentum for MyDay.

COO

Healthcare

CooperSurgical revenues were $342 million, up 4.5% reported and 2% organic, with fertility up 6% and office/surgical up 3%.
CooperVision revenues were $718 million, up 6.3% reported and 2.4% organic, with softness in Clarity and e-commerce in Asia Pac.
Free cash flow was strong at $165 million with CapEx of $97 million, and net debt declined to $2.35 billion.
Gross margin improved by 70 basis points to 67.3%, supported by efficiency gains, mix, and positive foreign exchange.
Non-GAAP earnings grew 15% year-over-year to $1.10 per share, driven by margin improvements and operational efficiency.
Operating income rose 8% with operating margin expanding to 26.1%, reflecting disciplined cost management.
Q3 consolidated revenues increased 5.7% year-over-year to $1.06 billion, with 2% organic growth.